Australia Markets open in 3 hrs 44 mins

CSL Limited (CSL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
285.50+1.95 (+0.69%)
At close: 04:10PM AEDT
Full screen
Previous close283.55
Bid285.40 x 0
Ask285.50 x 0
Day's range283.98 - 286.49
52-week range254.30 - 314.28
Avg. volume752,939
Market cap137.673B
Beta (5Y monthly)0.19
PE ratio (TTM)37.69
EPS (TTM)7.57
Earnings date14 Feb 2023
Forward dividend & yield3.18 (1.04%)
Ex-dividend date06 Sept 2022
1y target est326.44
  • PR Newswire

    Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV

    Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that Tavneos® has been included in the revised EULAR AAV management recommendations, as one of several important updates in the 2022 version. As part of a strategy to substantially reduce exposure to glucocorticoids, Tavneos® should be considered a therapy option in combination with rituximab or cyclophosphamide for induction of remission in patients with active granulomatosis with polyangiitis (GPA) or microscopic polyang

  • PR Newswire

    CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts

    Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts. The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory (BSL-3) in Waltham. The site will serve as CSL's central hub for current and future vaccine design.

  • PR Newswire

    The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE

    Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The study met its primary and secondary